Pulmonary arterial hypertension patient registry — Hospital Italiano de Buenos Aires

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Institutional Registry at Hospital Italiano de Buenos Aires enrolls adults with WHO Group 1 pulmonary arterial hypertension using 2022 ESC/ERS hemodynamic criteria. It combines prospectively enrolled incident cases with prevalent HMO patients who were diagnosed before the registry began. Clinical, hemodynamic, treatment, and outcome data are recorded to characterize disease course and real‑world management. As an observational single‑center registry, it does not assign interventions but documents routine clinical care.

Why it matters

Who can join: the full rules

* Inclusion Criteria:

  1. Diagnosed with PAH WHO group 1 (2022 ESC/ESR guidelines criteria) as the presence of a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest with pulmonary arterial wedge pressure (PAWP) \>15 mmHg and pulmonary vascular resistance (PVR) \>2 WU, according to the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
  2. Included in the institutional registry of PAH of Hospital Italiano de Buenos Aires
  3. Aged ≥18 years at the index date.
* Exclusion Criteria History of lung transplantation surgery previously the baseline period

Where it's running

• Hospital Italiano de Buenos Aires
  Buenos Aires, Buenos Aires, Argentina Recruiting

Study contacts

• Principal investigator: Ignacio M Bluro, MD — Hospital Italiano de Buenos Aires
• Study coordinator: Ignacio M Bluro, MD
• Email: ignacio.bluro@hospitalitaliano.org.ar
• Phone: +541149590200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PADN treatment for pulmonary arterial hypertension

  This project will try pulmonary artery denervation (PADN) with the Enhancor radiofrequency catheter in people with pulmonary arterial hypertension who underwent the procedure since March 2024 to collect real-world outcomes.

  Recruiting Pulnovo Medical (Wuxi) Co., Ltd. · Nanjing, Jiangsu · NCT07039604

• Understanding how low-load leg exercises affect muscle and blood flow in PAH patients

  This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07781709

• Sotatercept in Japanese children with pulmonary arterial hypertension

  This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.

  Recruiting at 3 sites Phase 2 Merck Sharp & Dohme LLC · Izumi, Osaka and 2 other locations · NCT07646860

• DIAG723 in Adults With HHT

  A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.

  Recruiting at 3 sites Phase 1/2 Diagonal Therapeutics, Inc. · Camperdown, New South Wales and 10 other locations · NCT07623525

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

• Sotatercept in Indian adults with pulmonary arterial hypertension on standard therapy

  This study tests whether adding sotatercept to current PAH medicines is safe and tolerable for adults with PAH in India.

  Recruiting at 3 sites Phase 4 Merck Sharp & Dohme LLC · Hyderabad, Andhra Pradesh and 2 other locations · NCT07600723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.